FDA Approves First Next-Generation Sequencing Test for Minimal Residual Disease of ALL and Multiple MyelomaOn September 28, 2018, the U.S. Food and Drug Administration (FDA) approved the first next-generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute... By Emily DownwardBookmark for later Reactions 0 reactions Comments1 comments
FDA Approves Copiktra for CLL/SLL and Follicular LymphomaOn September 24, 2018, the U.S. Food and Drug Administration (FDA) approved a new treatment for certain types of blood cancer: Copiktra (duvelisib). Manufactured by Verastem, Copiktra is approved to... By Emily DownwardBookmark for later Reactions 0 reactions Comments0 comments
Used or Considered CAR T-Cell Therapy? We Want to Hear From You!Have you had CAR T-cell therapy or considered it? If so, we’d like to hear from you. Please enter your email information below and we will contact you for a... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Lumoxiti for Hairy Cell LeukemiaOn September 13, 2018, the U.S. Food and Drug Administration (FDA) approved a new treatment option for adults with hairy cell leukemia (HCL) who have tried at least two prior... By Emily DownwardBookmark for later Reactions 0 reactions Comments0 comments
How's Your Relationship with Your Doctor? Take our Survey!Do you feel heard by your doctor? Do your questions get answered? We want to hear from you! We’re conducting a survey to learn more about your relationship with your... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves First Non-Chemotherapy Combination for Waldenstrom MacroglobulinemiaThe U.S. Food and Drug Administration (FDA) has approved the combination of Imbruvica® (ibrutinib) with Rituxan® (rituximab) for the treatment of Waldenstrom macroglobulinemia in adults. This is the first non-chemotherapy... By Pamela MunnellyBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Poteligeo for Rare Types of Non-Hodgkin LymphomaThe U.S. Food and Drug Administration (FDA) has approved Poteligeo (mogamulizumab-kpkc), a targeted treatment for people with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), who have previously... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
First Targeted Treatment for Relapsed or Refractory AML with IDH1 MutationThe U.S. Food and Drug Administration (FDA) has approved the first targeted treatment for people with acute myeloid leukemia (AML) that has relapsed or is refractory (hasn’t responded to previous... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Take the Impact of Cancer Survey!Managing life with cancer can be incredibly difficult. While some treatments and side effects have become common knowledge, there is so much more about life after a cancer diagnosis that... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
FDA Approves Keytruda for Refractory or Relapsed Primary Mediastinal Large B-Cell LymphomaThe U.S. Food and Drug Administration (FDA) has recently given accelerated approval for Keytruda® (pembrolizumab) to treat adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL) or... By Pamela MunnellyBookmark for later Reactions 0 reactions Comments0 comments
FDA Expands Venclexta Approval for Broader Treatment of CLL and SLLThe U.S. Food and Drug Administration (FDA) has recently expanded the approval for Venclexta® (venetoclax). Venclexta is now approved to treat chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)... By Emily DownwardBookmark for later Reactions 0 reactions Comments0 comments
Take the Clinical Trial Patient Experience Survey!Have you participated in a clinical trial? We want to hear more about your experience! We are conducting a short survey to understand how patients are involved in the clinical... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
Expanded Approval for Darzalex – Newly Diagnosed, Transplant-Ineligible Multiple MyelomaThe U.S. Food and Drug Administration (FDA) has recently expanded the usage of Darzalex® (daratumumab): it is now approved to be used in combination with Velcade® (bortezomib), melphalan, and prednisone... By Emily DownwardBookmark for later Reactions 0 reactions Comments0 comments
CAR T-Cell Therapy Kymriah Now Approved for Adult Diffuse Large B-Cell LymphomaThe U.S. Food and Drug Administration (FDA) recently expanded the approval of Kymriah™ (tisagenlecleucel) to include adults with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma... By Emily DownwardBookmark for later Reactions 0 reactions Comments0 comments
Newly Approved Front-Line cHL Treatment Was First in Over 40 YearsRecently, the United States Food and Drug Administration (FDA) announced the approval of a new front-line treatment combining Adcetris® (brentuximab vedotin) and chemotherapy for stage III or IV classical Hodgkin... By Editorial TeamBookmark for later Reactions 0 reactions Comments0 comments
